Inhibition of tumor necrosis factor improves sleep continuity in patients with treatment resistant depression and high inflammation

Brain, Behavior, and Immunity

Volumn 47, Issue , 2015, Pages 193-200

  Weinberger, Jeremy F ^a   Raison, Charles L ^a   Rye, David B ^a   Montague, Amy R ^a   Woolwine, Bobbi J ^a   Felger, Jennifer C ^a   Haroon, Ebrahim ^a   Miller, Andrew H ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

C reactive protein; Cytokines; Depression; Infliximab; Polysomnography; Sleep; Tumor necrosis factor

Indexed keywords

ANTIDEPRESSANT AGENT; C REACTIVE PROTEIN; HYPNOTIC SEDATIVE AGENT; INFLIXIMAB; MOOD STABILIZER; NEUROLEPTIC AGENT; PLACEBO; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; AROUSAL; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; ETHNICITY; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MINI MENTAL STATE EXAMINATION; POLYSOMNOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REM SLEEP; SLEEP DISORDER; SLEEP PARAMETERS; SLEEP STAGE; SLEEP WAKING CYCLE; SYMPTOMATOLOGY; TREATMENT RESISTANT DEPRESSION; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG EFFECTS; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; SLEEP;

ADULT; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; FEMALE; HUMANS; INFLAMMATION; INFLIXIMAB; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SLEEP; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84930718847     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2014.12.016     Document Type: Article

References (59)

1. Abad V.C., Sarinas P.S., Guilleminault C. Sleep and rheumatologic disorders. Sleep Med. Rev. 2008, 12:211-228.
2. Arfken C.L., Joseph A., Sandhu G.R., Roehrs T., Douglass A.B., Boutros N.N. The status of sleep abnormalities as a diagnostic test for major depressive disorder. J. Affect. Disord. 2014, 156:36-45.
3. Barbosa I.G., Huguet R.B., Mendonca V.A., Sousa L.P., Neves F.S., Bauer M.E., Teixeira A.L. Increased plasma levels of soluble TNF receptor I in patients with bipolar disorder. Eur. Arch. Psychiatry Clin. Neurosci. 2011, 261:139-143.
4. Benca R.M., Peterson M.J. Insomnia and depression. Sleep Med. 2008, 9:S3-9.
5. Benedict C., Scheller J., Rose-John S., Born J., Marshall L. Enhancing influence of intranasal interleukin-6 on slow-wave activity and memory consolidation during sleep. FASEB J. 2009, 23:3629-3636.
6. Capuron L., Gumnick J.F., Musselman D.L., Lawson D.H., Reemsnyder A., Nemeroff C.B., Miller A.H. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002, 26:643-652.
7. Chung E.S., Packer M., Lo K.H., Fasanmade A.A., Willerson J.T. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003, 107:3133-3140.
8. D'Mello C., Le T., Swain M.G. Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factoralpha signaling during peripheral organ inflammation. J. Neurosci. 2009, 29:2089-2102.
9. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., Lanctot K.L. A meta-analysis of cytokines in major depression. Biol. Psychiatry 2010, 67:446-457.
10. EEG arousals: scoring rules and examples: a preliminary report from the Sleep Disorders Atlas Task Force of the American Sleep Disorders Association. Sleep 1992, 15:173-184.
11. Faul F., Erdfelder E., Lang A., Buchner A. GPower 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Methods 2007, 39:175-191.
12. First MB S.R., Gibbon M., Williams J.B. Structured Clinical Interview for DSM-IV 1997, American Psychiatric Press, Washington, DC.
13. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975, 12:189-198.
14. Franzen P.L., Buysse D.J., Rabinovitz M., Pollock B.G., Lotrich F.E. Poor sleep quality predicts onset of either major depression or subsyndromal depression with irritability during interferon-alpha treatment. Psychiatry Res. 2010, 177:240-245.
15. Giles D.E., Jarrett R.B., Rush A.J., Biggs M.M., Roffwarg H.P. Prospective assessment of electroencephalographic sleep in remitted major depression. Psychiatry Res. 1993, 46:269-284.
16. Haensel A., Bardwell W.A., Mills P.J., Loredo J.S., Ancoli-Israel S., Morgan E.E., Heaton R.K., Dimsdale J.E. Relationship between inflammation and cognitive function in obstructive sleep apnea. Sleep Breath 2009, 13:35-41.
17. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960, 23:56-62.
18. Hendrickse W.A., Roffwarg H.P., Grannemann B.D., Orsulak P.J., Armitage R., Cain J.W., Battaglia J., Debus J.R., Rush A.J. The effects of fluoxetine on the polysomnogram of depressed outpatients: a pilot study. Neuropsychopharmacology 1994, 10:85-91.
19. Imeri L., Opp M.R. How (and why) the immune system makes us sleep. Nat. Rev. Neurosci. 2009, 10:199-210.
20. Irwin M.R., Wang M., Campomayor C.O., Collado-Hidalgo A., Cole S. Sleep deprivation and activation of morning levels of cellular and genomic markers of inflammation. Arch. Intern. Med. 2006, 166:1756-1762.
21. Irwin M.R., Wang M., Ribeiro D., Cho H.J., Olmstead R., Breen E.C., Martinez-Maza O., Cole S. Sleep loss activates cellular inflammatory signaling. Biol. Psychiatry 2008, 64:538-540.
22. Irwin M.R., Olmstead R., Valladares E.M., Breen E.C., Ehlers C.L. Tumor necrosis factor antagonism normalizes rapid eye movement sleep in alcohol dependence. Biol. Psychiatry 2009, 66:191-195.
23. Karson A., Demirtas T., Bayramgurler D., Balci F., Utkan T. Chronic administration of infliximab (TNF-alpha inhibitor) decreases depression and anxiety-like behaviour in rat model of chronic mild stress. Basic Clin. Pharmacol. Toxicol. 2013, 112:335-340.
24. Kerkhofs M., Rielaert C., de Maertelaer V., Linkowski P., Czarka M., Mendlewicz J. Fluoxetine in major depression: efficacy, safety and effects on sleep polygraphic variables. Int. Clin. Psychopharmacol. 1990, 5:253-260.
25. Krueger J.M. The role of cytokines in sleep regulation. Curr. Pharm. Des. 2008, 14:3408-3416.
26. Krueger J.M., Obal F.J., Fang J., Kubota T., Taishi P. The role of cytokines in physiological sleep regulation. Ann. N. Y. Acad. Sci. 2001, 933:211-221.
27. Kupfer D.J., Ehlers C.L. Two roads to rapid eye movement latency. Arch. Gen. Psychiatry 1989, 46:945-948.
28. Lam R.W. Sleep disturbances and depression: a challenge for antidepressants. Int. Clin. Psychopharmacol. 2006, 21(Suppl 1):S25-29.
29. Mayers A.G., Baldwin D.S. Antidepressants and their effect on sleep. Hum. Psychopharmacol. 2005, 20:533-559.
30. Mehta D., Raison C.L., Woolwine B.J., Haroon E., Binder E.B., Miller A.H., Felger J.C. Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression. Brain Behav. Immun. 2013, 31:205-215.
31. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 2009, 65:732-741.
32. Motivala S.J., Sarfatti A., Olmos L., Irwin M.R. Inflammatory markers and sleep disturbance in major depression. Psychosom. Med. 2005, 67:187-194.
33. Mullington J., Korth C., Hermann D.M., Orth A., Galanos C., Holsboer F., Pollmacher T. Dose-dependent effects of endotoxin on human sleep. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2000, 278:R947-955.
34. Musselman D.L., Lawson D.H., Gumnick J.F., Manatunga A.K., Penna S., Goodkin R.S., Greiner K., Nemeroff C.B., Miller A.H. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N. Engl. J. Med. 2001, 344:961-966.
35. Nutt D., Wilson S., Paterson L. Sleep disorders as core symptoms of depression. Dialogues Clin. Neurosci. 2008, 10:329-336.
36. Opp M.R. Cytokines and sleep. Sleep Med. Rev. 2005, 9:355-364.
37. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon R.O., Criqui M., Fadl Y.Y., Fortmann S.P., Hong Y., Myers G.L., Rifai N., Smith S.C., Taubert K., Tracy R.P., Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511.
38. Persoons P., Vermeire S., Demyttenaere K., Fischler B., Vandenberghe J., Van Oudenhove L., Pierik M., Hlavaty T., Van Assche G., Noman M., Rutgeerts P. The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab. Aliment. Pharmacol. Ther. 2005, 22:101-110.
39. Petersen T., Papakostas G.I., Posternak M.A., Kant A., Guyker W.M., Iosifescu D.V., Yeung A.S., Nierenberg A.A., Fava M. Empirical testing of two models for staging antidepressant treatment resistance. J. Clin. Psychopharmacol. 2005, 25:336-341.
40. Prather A.A., Rabinovitz M., Pollock B.G., Lotrich F.E. Cytokine-induced depression during IFN-alpha treatment: the role of IL-6 and sleep quality. Brain Behav. Immun. 2009, 23:1109-1116.
41. Prather A.A., Vogelzangs N., Penninx B.W. Sleep duration, insomnia, and markers of systemic inflammation: Results from the Netherlands Study of Depression and Anxiety (NESDA). J. Psychiatr. Res. 2015, 60:95-102.
42. Quan N., Banks W.A. Brain-immune communication pathways. Brain Behav. Immun. 2007, 21:727-735.
43. Raison C.L., Rye D.B., Woolwine B.J., Vogt G.J., Bautista B.M., Spivey J.R., Miller A.H. Chronic interferon-alpha administration disrupts sleep continuity and depth in patients with hepatitis C: association with fatigue, motor slowing, and increased evening cortisol. Biol. Psychiatry 2010, 68:942-949.
44. Raison C.L., Rutherford R.E., Woolwine B.J., Shuo C., Schettler P., Drake D.F., Haroon E., Miller A.H. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013, 70:31-41.
45. Ranjbaran Z., Keefer L., Stepanski E., Farhadi A., Keshavarzian A. The relevance of sleep abnormalities to chronic inflammatory conditions. Inflamm. Res. 2007, 56:51-57.
46. Rechtschaffen A.K.A. A Manual of Standard Terminology: Techniques and Scoring System for Sleep Stages in Human Subjects 1968, U.S. Government Printing Office, Washington, DC.
47. Rush A.J., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Warden D., Niederehe G., Thase M.E., Lavori P.W., Lebowitz B.D., McGrath P.J., Rosenbaum J.F., Sackeim H.A., Kupfer D.J., Luther J., Fava M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 2006, 163:1905-1917.
48. Rutgeerts P., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., Rachmilewitz D., Wolf D.C., Olson A., Bao W., Hanauer S.B. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004, 126:402-413.
49. Schroder J., Stuber F., Gallati H., Schade F.U., Kremer B. Pattern of soluble TNF receptors I and II in sepsis. Infection 1995, 23:143-148.
50. Tamaki S., Yamauchi M., Fukuoka A., Makinodan K., Koyama N., Tomoda K., Yoshikawa M., Kimura H. Production of inflammatory mediators by monocytes in patients with obstructive sleep apnea syndrome. Intern. Med. 2009, 48:1255-1262.
51. Thase M.E., Fasiczka A.L., Berman S.R., Simons A.D., Reynolds C.F. Electroencephalographic sleep profiles before and after cognitive behavior therapy of depression. Arch. Gen. Psychiatry 1998, 55:138-144.
52. Thase M.E. Depression and sleep: pathophysiology and treatment. Dialogues Clin. Neurosci. 2006, 8(2):217-226.
53. Trivedi M.H., Rush A.J., Ibrahim H.M., Carmody T.J., Biggs M.M., Suppes T., Crismon M.L., Shores-Wilson K., Toprac M.G., Dennehy E.B., Witte B., Kashner T.M. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol. Med. 2004, 34:73-82.
54. Tsuno N., Besset A., Ritchie K. Sleep and depression. J. Clin. Psychiatry 2005, 66:1254-1269.
55. Tweedie D., Sambamurti K., Greig N.H. TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. Curr. Alzheimer Res. 2007, 4:378-385.
56. Tyring S., Gottlieb A., Papp K., Gordon K., Leonardi C., Wang A., Lalla D., Woolley M., Jahreis A., Zitnik R., Cella D., Krishnan R. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006, 367:29-35.
57. Wohleb E.S., McKim D.B., Shea D.T., Powell N.D., Tarr A.J., Sheridan J.F., Godbout J.P. Re-establishment of anxiety in stress-sensitized mice is caused by monocyte trafficking from the spleen to the brain. Biol. Psychiatry 2014, 75:970-981.
58. Yue H.J., Mills P.J., Ancoli-Israel S., Loredo J.S., Ziegler M.G., Dimsdale J.E. The roles of TNF-alpha and the soluble TNF receptor I on sleep architecture in OSA. Sleep Breath 2009, 13:263-269.
59. Zamarron C., Maceiras F., Mera A., Gomez-Reino J.J. Effect of the first infliximab infusion on sleep and alertness in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 2004, 63:88-90.